Crossmark Global Holdings, Inc. Corcept Therapeutics Inc Transaction History

Crossmark Global Holdings, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 10, 2022	SELL	$17.1 - $23.34 $562,761 - $768,119	-32,910 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$19.68 - $22.53 $647,668 - $741,462	32,910 New	32,910 $648,000
Q3 2021 Oct 13, 2021	SELL	$19.68 - $22.53 $650,620 - $744,841	-33,060 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$19.97 - $24.43 $3,594 - $4,397	180 Added 0.55%	33,060 $727,000
Q1 2021 Apr 15, 2021	BUY	$23.49 - $30.56 $3,993 - $5,195	170 Added 0.52%	32,880 $782,000
Q4 2020 Jan 14, 2021	BUY	$16.78 - $27.3 $172,397 - $280,480	10,274 Added 45.79%	32,710 $856,000
Q3 2020 Oct 08, 2020	BUY	$12.46 - $19.98 $5,432 - $8,711	436 Added 1.98%	22,436 $390,000
Q2 2020 Aug 14, 2020	BUY	$11.0 - $18.26 $18,700 - $31,042	1,700 Added 8.37%	22,000 $370,000
Q4 2019 Feb 06, 2020	BUY	$12.06 - $16.96 $10,492 - $14,755	870 Added 4.48%	20,300 $246,000
Q3 2019 Oct 09, 2019	BUY	$10.41 - $14.66 $1,977 - $2,785	190 Added 0.99%	19,430 $275,000
Q2 2019 Jul 09, 2019	SELL	$9.78 - $12.76 $8,508 - $11,101	-870 Reduced 4.33%	19,240 $215,000
Q1 2019 May 02, 2019	SELL	$10.03 - $15.71 $1,103 - $1,728	-110 Reduced 0.54%	20,110 $236,000
Q4 2018 Jan 31, 2019	SELL	$11.29 - $17.19 $164,946 - $251,145	-14,610 Reduced 41.95%	20,220 $270,000
Q3 2018 Nov 08, 2018	BUY	$12.27 - $15.65 $5,521 - $7,042	450 Added 1.31%	34,830 $488,000
Q2 2018 Jul 31, 2018	BUY	$15.3 - $19.69 $31,671 - $40,758	2,070 Added 6.41%	34,380 $540,000
Q1 2018 Apr 16, 2018	BUY	$14.59 - $25.5 $471,402 - $823,905	32,310 New	32,310 $531,000

376

87.5M

1.16M

707K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $7.29B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.